|Articles|June 1, 2012

2012 e-media kit - new contact page

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development

ByAndy Studna, Senior Editor

July 13th 2026

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

ByAndy Studna, Senior Editor

July 10th 2026

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

ByGaynor Anders,Andy Studna, Senior Editor

July 10th 2026

Medical affairs are often well positioned to identify gaps between how studies are designed and how therapies may ultimately be experienced by patients and physicians. Credit: Stock.Adobe.com/Jacob Lund

Bringing the Voice of Clinical Practice and Patients into Drug Development

ByNatalia Borinshteyn, MD, PhD

July 10th 2026

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

ByAndy Studna, Senior Editor

July 10th 2026

2012 e-media kit - new contact page

Related Content

ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

Trending on Applied Clinical Trials Online

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

Bringing the Voice of Clinical Practice and Patients into Drug Development